


Oritavancin diphosphate

Cat. No.:	HY-B1831A
CAS No.:	192564-14-0
Molecular Formula:	C ₈₆ H ₁₀₃ Cl ₃ N ₁₀ O ₃₄ P ₂
Molecular Weight:	1989.09
Target:	Bacterial; Antibiotic
Pathway:	Anti-infection
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	H ₂ O : 50 mg/mL (25.14 mM; Need ultrasonic)				
	DMSO : 25 mg/mL (12.57 mM; ultrasonic and warming and heat to 60°C)				
		Mass			
	Solvent	Concentration	1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM		0.5027 mL	2.5137 mL	5.0274 mL
	5 mM		0.1005 mL	0.5027 mL	1.0055 mL
	10 mM		0.0503 mL	0.2514 mL	0.5027 mL
Please refer to the solubility information to select the appropriate solvent.					
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (1.05 mM); Clear solution				
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.08 mg/mL (1.05 mM); Clear solution				
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (1.05 mM); Clear solution				

BIOLOGICAL ACTIVITY

Description	Oritavancin diphosphate (LY333328 diphosphate) is an orally active glycopeptide antibiotic with activity against gram-positive organisms. Oritavancin diphosphate shows antibacterial effect against multidrug-resistant <i>S. pneumoniae</i> . Oritavancin diphosphate inhibits cell wall synthesis and disrupts the membrane potential ^{[1][2]} .
IC₅₀ & Target	Glycopeptide

CUSTOMER VALIDATION

- Emerg Microbes Infect. 2019;8(1):503-515.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Coyle EA, et al. Activity of oritavancin (LY333328), an investigational glycopeptide, compared to that of vancomycin against multidrug-resistant *Streptococcus pneumoniae* in an in vitro pharmacodynamic model. *Antimicrob Agents Chemother.* 2001 Mar;45(3):706-9.
- [2]. Arhin FF, et al. Effect of polysorbate 80 on oritavancin binding to plastic surfaces: implications for susceptibility testing. *Antimicrob Agents Chemother.* 2008 May;52(5):1597-1603.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA